HELP KEEP THEM OUT OF THE RED AND IN THE GREEN

Zestril
Lisinopril ICI

PRESCRIBING NOTES

Consult data sheet before prescribing.

USE: All grades of essential hypertension and renovascular hypertension. Congestive heart failure (adjunctive therapy).

PRESENTATION: Tablets containing 2.5mg, 5mg, 10mg or 20mg lisinopril (Zestril).

DOSE AND ADMINISTRATION: Hypertension - initially 2.5mg daily, a 2.5mg dose seldom achieves a therapeutic response; adjust dose according to response. Maintenance usually 10-20mg once-daily. Maximum is 40mg daily. Diuretic-treated patients - if possible stop diuretic 2-3 days before starting 'Zestril'. Resume diuretic later if desired.

Congestive heart failure: (adjunctive therapy) - initially 2.5mg daily in hospital under close medical supervision, increasing to 5-20mg once-daily according to response.

Impaired renal function: May require a lower maintenance dose. 'Zestril' is dialysable.

Elderly patients: No change from standard recommendations.

CONTRAINDICATIONS: Pregnancy - stop therapy if suspected. Hypersensitivity to 'Zestril'. Patients reacting with angioedema or oedema to previous ACE inhibitor treatment.

PRECAUTIONS: Assessment of renal function is recommended. Renal insufficiency, renovascular hypertension, surgery/anesthesia, possibility of hypotension especially in ischaemic heart disease and cerebrovascular disease. Combination with anti-hypertensives may increase hypotensive effect. Sometimes increased blood urea and creatinine and/or cases of renal insufficiency if given with diuretics. Minimizes thiazide-induced hypokalaemia and hyperuricaemia. Potassium supplements, potassium-sparing diuretics and potassium-containing salt substitutes not recommended. Indomethacin may reduce hypotensive effect. Possible reduced response in Afro-Caribbean patients. Use with caution in breastfeeding mothers. Do not use in aortic stenosis or outflow tract obstruction or cor pulmonale. Monitor lithium serum levels if lithium salts administered.

SIDE EFFECTS: Dizziness, headache, diarrhoea, fatigue, cough and nausea. Less frequently, rash and asthma. Rarely, angioedema and other hypersensitivity reactions; renal failure; symptomatic hypotension (especially f volume-depleted), severe hypotension (more likely if severe heart failure, palpitation; hyperuricaemia, increases in liver enzymes and serum bilirubin (usually reversible on discontinuation of 'Zestril') and impotence.

PRODUCT LICENCE NUMBERS AND BASIC NHS COSTS: 'Zestril' 2.5mg 29/0200/28 tablets. £1.84. 5mg 29/0204/28 tablets. £2.33. 10mg 29/0205/28 tablets. £2.62. 20mg 29/0206/28 tablets. £2.95.

'Zestril' is a trademark.

Further information is available from: ICI Pharmaceuticals, King's Court, Water Lane, Wilsden, Cheshire SK9 5AZ.

THE LISA SAINSBURY FOUNDATION

RESIDENTIAL WORKSHOP
(2 NIGHTS)

‘Terminal Care in the Community’

Monday 21st September to Wednesday 23rd September 1992
Holland House, Croptorne, Pershore, Worcester

Family practitioners are invited to join a group looking at terminal care in the community. The major issue to be covered will be principles of symptom control, the team approach to management of care particularly highlighting the problems of communication and the needs of the bereaved. This workshop is designed so that considerable benefit can be gained if a family practitioner is accompanied by a community nurse from the same practice.

PGEA approved. Cost £40 plus accreditation fee.


Imperial College of Science, Technology and Medicine
University of London

The Annual Intensive 5-day Course on MEDICAL ETHICS for Medical & Nursing Teachers, Medical Practitioners & Members of Ethics Committees

To be held in London
7 - 11 September 1992

The course will clarify the meaning and significance of key ethic concepts; outline important types of ethical theory and their relevance to medical ethics. Offer a conceptual framework suitable for the ethical analysis of medico-moral problems in a variety of professional contexts. Give opportunities to participants — under supportive conditions — to articulate their current medico-moral attitudes and explore reasoned arguments that challenge their existing assumptions and ethical stances.

PGEA & BPMF HOSPITAL
STUDY LEAVE APPROVED 1992

For further details please contact:
Pamela Manser
Continuing Education Centre, Imperial College
Room 558 Sherfield Building, London SW7 2AZ, UK
Tel. No. 071 225 8666/7. Fax. 071 225 8668

17th INTERNATIONAL CONGRESS OF LIFE ASSURANCE MEDICINE

BARMICAN CENTRE, CITY OF LONDON
6 - 10 SEPTEMBER 1992

Life assurance medicine is changing in parallel with the development of medical science and is influenced by economic and social factors. For those from all over the world who are involved in life assurance medicine the ICLAM Congress offers an unparalleled opportunity for an update on recent medical advances which is reflected in the Scientific Programme. In conjunction with the Scientific Programme, there are also full Social and Accompanying Guest Programmes.

For a copy of the Congress Invitation and registration form, please contact the Congress Secretariat at the address detailed below:

Congress Secretariat:
Conference Associates and Services Ltd — ICLAM
Congress House
55 New Cavendish Street
London W1M 7RE, UK
Telephone: 071 486 0531 Facsimile: 071 935 7559

British Journal of General Practice, May 1992
FELDENE GEL

PRESCRIBING INFORMATION
Indications: FELDENE Gel is effective in the treatment of osteoarthritis of superficial joints and acute musculoskeletal disorders. Dosage: For external use only. Occlusive dressings should not be used. Apply one gram of FELDENE Gel and rub into the affected site three to four times daily leaving no residual material on the skin. Therapy should be reviewed after 4 weeks.

Contra-indications:
Precautions: Contra-indicated in patients who have previously shown a hypersensitivity to FELDENE Gel or piroxicam in any of its forms, aspirin or other non-steroidal anti-inflammatory agents. If local irritation develops, discontinue FELDENE Gel. Keep away from the eyes and mucosal surfaces. Do not apply to sites affected by open skin lesions, dermatitis or infection. Use in children: Not recommended. Use in pregnancy and lactation: The safety of FELDENE Gel during pregnancy and lactation has not been established. Side-effects: Mild or moderate local reactions at the application site. Mild but transient skin discoloration and staining of clothing have been noted when FELDENE Gel is not rubbed in completely. Package Quantities and Basic NHS Cost: FELDENE Gel 10g tube — CT77

Further information on request.

Pfizer
Pfizer Limited, Sandwich, Kent
*Trade Mark

BRINGS RELIEF